Disabling Cerebral Ischemic Stroke
Conditions
Interventions
Intervention Group:DELP Treatment
Control group:Routine treatment
Sponsors
Hua Shan Hospital, School of Medicine, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. People who suffered the Cerebral Ischemic Stroke or the first time, or the CIS outbreak before but it did not leave a deficit in neurological function; 2. Aged 18-70 years old, male or female; 3. There are definite signs of the nervous system, and the points of NIHSS is from 4 to 22; 4. People who did not receive intravenous thrombolysis or endovascular treatment within 48 hours; 5. Serum LDL-C=2.6mmol/L; 6. Blood pressure =180/110mmHg; 7. Voluntarily signed the informed consent of the patients.
Exclusion criteria
Exclusion criteria: 1. CT shows that people with cerebral hemorrhage, or with a history of cerebral hemorrhage; 2. Patients with previous calcium allergy; 3. People have a metal instrument implanted and cannot do magnetic resonance examination (Patients without iron and magnetic metal implants are not included); 4. People with abnormal liver and kidney function (Serum bilirubin, alanine aminotransferase, and aspartate aminotransferase are 1.5 times higher than the upper limit of normal, and urea nitrogen and creatinine are 1.5 times higher than the upper limit of normal); 5. People with severe abnormal coagulation function, platelets less than 50,000/uL, or severely abnormal coagulation function; 6. The pregnant and breast-feeding people; 7. People who can't cooperate, such as psychosis, dementia, etc.; 8. People with Hypoproteinemia 9. People with a definite intracranial aneurysm or vascular malformation 10. Patients with cardiogenic stroke caused by acute rheumatic fever, endocarditis, etc., or stroke caused by brain infection, brain trauma, tumor, epilepsy, etc. 11. People with other serious comorbidity(Such as, people with combined malignant hypertension, severe heart disease, respiratory failure and they unable to undergo extracorporeal circulation or combined malignancy; Due to the existence of comorbidity, people who are expected to survive less than 6 months) 12. People who are being treated with experimental drugs and experimental instruments 13. People with contraindications to DELP treatmentPeople with serious heart and lung diseases who cannot undergo cardiopulmonary bypassAll kinds of acute hemorrhagic diseases, such as acute hemorrhagic cerebral apoplexy, severe peptic ulcer with hemorrhage; all kinds of diseases with high risk of bleeding, such as hemophilia, severe liver failure, etc.; 14. Doctors think that people who are not suitable to participate in this study; 15. People who recently participated in clinical experiments.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood lipids; | — |
Secondary
| Measure | Time frame |
|---|---|
| Routine blood test;Liver function;;Renal function;Blood coagulation;Electrolytic;Inflammatory factor;Blood sugar; | — |
Countries
China
Contacts
Public ContactQiang Dong
Department of Neurology, Hua Shan Hospital, School of Medicine, Fudan University
Outcome results
None listed